Technology | June 10, 2015

Cordis Corporation Expands Cordis Crossing Portfolio With New Support, Re-entry Catheters

New devices indicated for treatment of chronic total occlusions

Cordis Corp., Cordis Crossing Portfolio, Elitecross, Outback Elite, CTO

June 10, 2015 - Cordis Corp. announced the launch of the new Elitecross support catheter in the United States and Outback Elite re-entry catheter in the United States, Europe and Japan. This expands the Cordis Crossing Portfolio for treatment of chronic total occlusions (CTO), a suite of specialty and workhorse solutions designed to support physicians in crossing the most complex lesions.

A CTO occurs when the accumulation of plaque becomes so severe that it results in a complete or nearly complete blockage of the vessel. When this occurs, physicians must find a way to cross the occlusion in order to complete treatment of the lesion using interventional techniques.

"New and dedicated CTO crossing wires, re-entry devices and crossing catheters, combined with advancing technique have led to a significant improvement in success rates of CTO treatment in recent years," said Jihad Mustapha, M.D., FACC, FSCAI, director of heart and vascular at Metro Health Hospital in Wyoming, Michigan. "The expanded Cordis Crossing portfolio enables physicians to further improve treatment success, and deliver the best possible care to the patients that rely on us every day."

The Cordis Crossing Portfolio reduces the complexity of challenging cases and provides a comprehensive crossing solution of specialty and workhorse devices. The new Elitecross support catheter features a braided shaft, tapered tip, lubricious hydrophilic coating and ultra low-friction inner lumen to enhance trackability over the guidewire. The device is designed to provide additional support to the distal portion of diagnostic or interventional devices, and is compatible with the Frontrunner XP CTO catheter as well as other ancillary devices.

The redesigned Outback Elite re-entry catheter enables faster and more precise re-entry into the true lumen in the most challenging cases, and represents the first ever re-entry device available in Japan. The device was redesigned with an ergonomic handle and torque control location, enabling single-handed operation by the user. The addition of an 80 cm shaft length will aid in optimizing procedures by reducing the length of shaft outside the patient. These new features combined with a redesigned package make the Outback Elite a more convenient, precision re-entry tool for the toughest lesions of peripheral vascular disease. In a recent study by Gandini et al., the Outback re-entry catheter was shown to have a higher success rate of precision re-entry versus manual wire techniques.

Cordis expects to launch the Elitecross in Europe and Japan in the coming months.

For more information:

Related Content

FDA Issues Letter About Paclitaxel Coated Balloons and Eluting Stents
News | Peripheral Artery Disease (PAD) | January 17, 2019
The U.S. Food and Drug Administration (FDA) issued a letter Jan. 17, 2019, to healthcare providers regarding a recent...
New Appropriate Use Criteria Released for Peripheral Artery Interventions
News | Peripheral Artery Disease (PAD) | December 19, 2018
A new set of appropriate use criteria (AUC) released Dec. 17 by a group of cardiovascular professional societies...
Lithotripsy Safe and Effective in Calcified Stenotic Peripheral Arteries
News | Peripheral Artery Disease (PAD) | December 04, 2018
New results from the DISRUPT PAD II study showed no perforations, embolization, reflow or abrupt closures with the...
Lutonix 014 Drug-Coated Balloon Safe and Effective Below the Knee
News | Peripheral Artery Disease (PAD) | November 07, 2018
The Lutonix Drug-Coated Balloon (DCB) showed statistically significant safety equivalence with a standard percutaneous...
Lokai Medical to Distribute NuCryo Vascular PolarCath Balloon Dilatation System in U.S.
News | Peripheral Artery Disease (PAD) | August 14, 2018
NuCryo Vascular announced that the company has signed a commercialization agreement with Lokai Medical, a specialty...
PQ Bypass Effective in Treating Extremely Long SFA Lesions at 12 Months
News | Peripheral Artery Disease (PAD) | July 02, 2018
The PQ Bypass Detour System showed promising 12-month durability for patients with extremely long blockages in the...
SCAI Releases Consensus Guidelines for Femoral-Popliteal Arterial Interventional Device Selection
News | Peripheral Artery Disease (PAD) | May 15, 2018
The Society for Cardiovascular Angiography and Interventions (SCAI) has released new guidelines to address the...
SCAI Launches Diagnosis and Treatment Toolkit for Peripheral Artery Disease
News | Peripheral Artery Disease (PAD) | May 14, 2018
The Society for Cardiovascular Angiography and Interventions (SCAI) announced the launch of the SCAI PAD Diagnosis and...
Critical Limb Ischemia Treatment Shows No Improvement at Three Months
News | Peripheral Artery Disease (PAD) | March 23, 2018
Patients with foot ulcers or gangrene who received the experimental drug JVS-100 did not show evidence of faster wound...
Overlay Init